SPA
ARCT icon

Sherbrooke Park Advisers’s Arcturus Therapeutics ARCT Stock Holding History

Sherbrooke Park Advisers’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,786
Closed -$200K – 600
2024
Q4 		$200K Buy
+11,786
New +$222K 0.06% 594
2024
Q3 		– Sell
-19,922
Closed -$485K – 899
2024
Q2 		$485K Buy
+19,922
New +$604K 0.08% 425

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sherbrooke Park Advisers's ARCT Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Arcturus Therapeutics (ARCT) in Q1 2025, closing a stake of 11,786 shares — an estimated $200K sold.

Sherbrooke Park Advisers first reported a position in ARCT in Q2 2024 and held it in 2 quarters. The position peaked at $485K in Q2 2024. 144 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Arcturus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,786 Arcturus Therapeutics shares in Q1 2025, an estimated $200K.
  • Sherbrooke Park Advisers first reported a position in Arcturus Therapeutics in Q2 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Arcturus Therapeutics position peaked at $485K in Q2 2024.
  • 144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.